Skip to main content
AmigoFish

FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival

From BioSpace · · 22 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing the Prescription Drug User Fee Act the day after launching its TrialBlazer initiative. Meanwhile, Definium Therapeutics notched another late-stage trial win for its LSD drug, and Novartis continues to reel from the company’s triple asset stumble.

Back to BioSpace · Report a problem